Semaglutide & Mental Health: Depression & Mood Effects

Mental health effects of semaglutide have become a growing area of interest — partly due to safety reports, partly due to surprising positive findings in research. Here is what the evidence actually shows.

The Safety Concern: What Prompted the Review

In 2023, the European Medicines Agency (EMA) and FDA began reviewing reports of suicidal ideation and self-harm in GLP-1 users. This triggered widespread media coverage and concern. However, upon completing their review of all available trial data, both agencies concluded that the current evidence does not establish a causal link between GLP-1 agonists and suicidal ideation or self-harm. The absolute number of reports was small, and obesity itself is a significant risk factor for depression and suicidality — making it difficult to separate drug effects from underlying condition.

Clinical Trial Data: No Signal for Depression

The STEP trials — the largest semaglutide weight management trials — did not show increased rates of depression, anxiety, or suicidal ideation in the semaglutide groups compared to placebo. The SELECT cardiovascular outcomes trial (over 17,000 participants, median follow-up 3.4 years) similarly showed no increased psychiatric adverse events.

The Positive Side: Emerging Evidence for Mood Benefits

Multiple large observational studies have found lower rates of depression diagnoses among GLP-1 users compared to matched controls. A 2023 study in JAMA Internal Medicine found GLP-1 users had significantly lower rates of new depression diagnoses. The mechanisms proposed include: direct GLP-1 receptor activity in limbic brain regions that regulate mood; reduction of neuroinflammation (increasingly linked to depression); and the substantial psychological benefits of meaningful weight loss — improved self-esteem, mobility, and body image all independently improve mood.

The “Food Noise” Effect and Mental Health

One of the most reported and least discussed effects of semaglutide is the dramatic reduction in “food noise” — the intrusive, persistent thoughts about food that many people with obesity experience. Many users describe this as profoundly mentally freeing. Constantly thinking about food, feeling out of control around eating, and experiencing shame cycles are associated with anxiety and low mood. When this mental burden lifts, many people report significant improvements in wellbeing that they did not expect.

When to Monitor Carefully

People with a pre-existing history of depression, anxiety, or suicidal ideation should discuss this with their prescriber before starting semaglutide and during treatment. This is not a contraindication — but it warrants closer monitoring and open communication. Anyone noticing new or worsening mood symptoms should contact their physician promptly.

Affiliate disclosure: This article contains affiliate links. See our Affiliate Disclosure.